Vaxxas Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
129
- Latest Deal Type
-
Series D
- Latest Deal Amount
-
$57.9M
- Investors
-
21
Vaxxas General Information
Description
Developer of a needle-free vaccine delivery platform designed to improve vaccine administration by delivering antigens directly into the skin to enhance immune responses. The company offers a proprietary microarray patch and applicator platform that targets immune cells in the epidermis and dermis, enabling vaccine developers and healthcare providers to improve vaccine delivery and immunization outcomes.
Contact Information
Website
www.vaxxas.comCorporate Office
- 240 MacArthur Avenue
- Hamilton, Queensland 4007
- Australia
Corporate Office
- 240 MacArthur Avenue
- Hamilton, Queensland 4007
- Australia
Vaxxas Timeline
Vaxxas Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 15. Later Stage VC (Series D) | 25-Aug-2025 | $57.9M | Completed | Generating Revenue | ||
| 14. Grant | 13-Jan-2025 | Completed | Clinical Trials - Phase 1 | |||
| 13. Grant | 23-Aug-2023 | Completed | Clinical Trials - Phase 1 | |||
| 12. Later Stage VC | 05-Dec-2022 | Completed | Clinical Trials - Phase 1 | |||
| 11. Grant | 02-Sep-2022 | Completed | Clinical Trials - General | |||
| 10. Grant | 01-Jan-2021 | Completed | Clinical Trials - General | |||
| 9. Later Stage VC | Completed | Clinical Trials - General | ||||
| 8. Grant | 05-Oct-2020 | Completed | Clinical Trials - General | |||
| 7. Grant | 17-Mar-2020 | $9.5M | $70.2M | Completed | Clinical Trials - General | |
| 6. Later Stage VC | 01-Jan-2020 | $30.9M | $70.2M | Completed | Clinical Trials - General |
Vaxxas Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | 12,000,000 | $1.95 | $1.95 | 1x | $1.95 | 27.68% | ||
| Series A | 15,024,436 | $0.65 | $0.65 | 1x | $0.65 | 34.66% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Vaxxas Comparisons
Industry
Financing
Details
Vaxxas Competitors (3)
One of Vaxxas’s 3 competitors is NanoPass Technologies, a Venture Capital-Backed company based in Nes Ziona, Israel.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NanoPass Technologies | Venture Capital-Backed | Nes Ziona, Israel | ||||
| PharmaJet | Venture Capital-Backed | Golden, CO | ||||
| MICRON Biotech | Venture Capital-Backed | Chengdu, China |
Vaxxas Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Vaxxas Patents
Vaxxas Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026055729-A1 | Rna-lnp formulations delivered by hd-map | Pending | 10-Sep-2024 | ||
| WO-2026020198-A1 | Manufacture of high density microprojection arrays | Pending | 24-Jul-2024 | ||
| WO-2026020194-A1 | Measles and rubella vaccine delivered by hd-map | Pending | 23-Jul-2024 | ||
| WO-2026020195-A1 | Nucleic acids delivered by hd-map | Pending | 23-Jul-2024 | ||
| AU-2025243613-A1 | Microprojection arrays | Pending | 29-Mar-2024 |
Vaxxas Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Vaxxas Investors (21)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| LGT Crestone Wealth Management | PE-Backed Company | Minority | ||
| SPRIM Global Investments | Holding Company | Minority | ||
| Wellcome Trust | Limited Partner | |||
| Australian Federal Government | Government | |||
| Biomedical Advanced Research and Development Authority | Government |
Vaxxas FAQs
-
When was Vaxxas founded?
Vaxxas was founded in 2011.
-
Where is Vaxxas headquartered?
Vaxxas is headquartered in Hamilton, Australia.
-
What is the size of Vaxxas?
Vaxxas has 129 total employees.
-
What industry is Vaxxas in?
Vaxxas’s primary industry is Drug Delivery.
-
Is Vaxxas a private or public company?
Vaxxas is a Private company.
-
What is the current valuation of Vaxxas?
The current valuation of Vaxxas is .
-
What is Vaxxas’s current revenue?
The current revenue for Vaxxas is .
-
How much funding has Vaxxas raised over time?
Vaxxas has raised $154M.
-
Who are Vaxxas’s investors?
LGT Crestone Wealth Management, SPRIM Global Investments, Wellcome Trust, Australian Federal Government, and Biomedical Advanced Research and Development Authority are 5 of 21 investors who have invested in Vaxxas.
-
Who are Vaxxas’s competitors?
NanoPass Technologies, PharmaJet, and MICRON Biotech are competitors of Vaxxas.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
